Heart Failure

MIRVAD (Mitral Repair Under Ventricular Assist Device): A Planned cVAD Strategy for High-Risk Secondary Mitral TEER

My Personal Algorithm for Primary PCI Complicated by Cardiogenic Shock

TCT 1134: Rescue Angioplasty During Cardiopulmonary Resuscitation in a Patient With Anterior Wall STEMI

TCT 1139: Impella CP Supported Primary PCI in Patient With Simultaneous Occlusions of Bilateral Coronary Artery

TCT 1532: ECMELLA Treatment of Severe Cardiogenic Shock in OHCA Survivor

How Do I Decide on Choice of Mechanical Circulatory Support in MI: A Personal Perspective

TCT 1379: Impella-Assisted Multivessel PCI in an Elderly Patient With Acute Myocardial Infarction-Related Cardiogenic Shock

TCT 1367: Arrhythmic Storm and Cardiogenic Shock Due to Spontaneous Coronary Artery Dissection of Left Circumflex With Extension to the Left Main Coronary Artery: Primary PCI Supported With Impella CP

TCT 1318: Salvage VA-ECMO and Left Main PCI for Refractory Left Main Coronary Vasospasm in a Transwoman Undergoing Gender Affirming Hormone Therapy

TCT 1363: Early Implementation of Impella CP Support in Patient With Cardiogenic Shock

Cardiogenic Shock: Recognition, Management, and the Role of thee Shock Team

My Perspective on MCS - Progress Achieved and Opportunities for Improvement

TCT 1297: Last Chance to Survive

TCT 1494: Early Implementation of ECPELLA in Refractory Cardiogenic Shock Due to Myocarditis 

The Conundrum of Clinical Trials in Cardiogenic Shock

Ivabridine in Cardiogenic Shock

Pulsatile ECMO

DPP3-Based Biotherapy in Cardiogenic Shock

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

Shock-Phenotype Matching Using Real-World Evidence: A New Paradigm for Prospective Enrollment in Clinical Trials of Acute MCS Devices in Cardiogenic Shock

Cardiogenic Shock: The Urgent Need for Innovation in Devices and Technologies for Shock

Potential Benefits of Decreasing HR: Adjuntive Therapies to Pumps

Istraoxime for Cardiogenic Shock

The Impella Portfolio of Devices for Cardiogenic Shock (Left-Sided Support)

Early Experience With the Supira Microaxial Flow Pump

Early Experience With the Magenta Elevate™ Micro-Axial Flow Pump

Innovations for RV Support in Shock

Innovations in Management of ECMO-Supported Patients

Clinical Trials for Cardiogenic Shock: Going Forwards, Backwards, or Sideways?

Risk Stratification: Thinking Beyond SCAI Staging

Deep Phenotyping in Cardiogenic Shock

Inotropes and Mortality in Patients With Cardiogenic Shock Due to Myocardial Infarction: Insights from the SWEDEHEART Registry

DoReMe: Are Inotropes Helpful or Harmful?

ECMO-Unload: Is This the Answer to ECLS-SHOCK?

Pulmonary Artery Catheter in Shock (PACCS)

The RECOVER IV Study Overview

Cardiogenic Shock in Stress Induced Cardiomyopathy Complicated by Left Ventricular Outflow Obstruction: Hemodynamic-Tailored Management

Initial Experience of ECMO and E-CPR in Cardiogenic Shock in a Tertiary Center in Mexico

Estimating the Effect of Mechanical Circulatory Support on Mortality, Complications, and Readmission Rates in Patients Admitted with ST-Elevation Myocardial Infarction with Cardiogenic Shock who underwent Percutaneous Coronary Intervention

IV Diltiazem Use in Patients with Atrial Fibrillation and Systolic Dysfunction

MCS in Cardiogenic Shock: Use It Selectively

We Need Shock and Arrest Centers (Pro)

Take Care of the Patient as Close to Home as Possible

State-of-the-art Lecture on Evidence for MCS in Cardiogenic Shock

Pro: Cardiogenic Shock Therapy Must Be Guided by Pulmonary Artery Catheter

Con: Cardiogenic Shock Therapy Need Not Be Guided by Pulmonary Artery Catheter

MCS in Cardiogenic Shock: Use It Routinely

MCS in Shock: Choosing the Right Device Based on Hemodynamic Criteria

MCS in Shock: Access Site Selection and Prevention of Access Site Complications

Optimal Antithrombotic Strategies in MCS Use

When to Perform Venting in VA-ECMO

RV Support: When and How?

The Conundrum of Clinical Trials in Cardiogenic Shock

Con: VA-ECMO is not the Option of Choice for Cardiogenic Shock

Pro: Most Patients With AMI Cardiogenic Shock Should Get MCS (Randomization Is Unethical)

Con: Favorable Data Is Lacking on MCS in AMI Cardiogenic Shock (Randomized Data Are Needed)

Pro: The IABP is the First-line MCS for Non-AMI Cardiogenic Shock

Con: The IABP is not a First-line MCS for Non-AMI Cardiogenic Shock

Pro: Percutaneous LVADs are the First Line MCS device of choice for Acute MI & Cardiogenic Shock

Con: Percutaneous LVADs are not the First Line MCS device of choice for Acute MI & Cardiogenic Shock

Pro: VA-ECMO is the Option of Choice for Cardiogenic Shock

Coronary Keynote Lecture: When and How to Choose IABP, Impella, TandemHeart, or ECMO in CS

Tinkering the Ticker: TandemHeart to TAVR

Staged Strategic Treatment Pathway During Unique Biventricular Failure Case

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre Cardiogenic Shock

Assessing RV Function in Cardiogenic Shock: When to Pull the Trigger on MCS

Role of Temporary MCS in Pulmonary Arterial Hypertension

Cardiogenic Shock: ECMO Supported TAVR

Cardiogenic Shock With MCS and Review of Shock Algorithm

Aortic Stenosis With Acute LV Unloading With Septostomy

Acute MR With MCS/TEER

Pulmonary Artery Catheter Use in Patients with Heart Failure Cardiogenic Shock (HF-CS): An Analysis from the Cardiogenic Shock Working Group (CSWG)

Influence of Body Surface Area, and Ventricular Dimensions on Impella 5.5 Outcomes

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Hot Topics on Regulatory Issues in Caridiogenic Shock - FDA Perspective

How Narrow or Broad Should Enrollment Criteria Be in Trials on Cardiogenic Shock to Achieve Clinically Interpretable Results?

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial on Cardiogenic Shock? What Are The Key Treatment Protocol Elements?

Cardiogenic Shock: Patient Phenotyping and Prognostication

Cardiogenic Shock: Customized Therapeutic Approaches in 2023

Impella for Cardiogenic Shock: High Expectations From Ongoing Studies

Should All ECMO Patients Receive LV Unloading (Include HYPO-ECMO)?

SSO2 for AMI Shock: The ISO-Shock Trial (AMI)

SEISMiC Trial: Isatroxime (lusi-inotrope) (HF shock)

When To Transition From Medical to Device-Based Therapy

What Do We Really Know About ECMO in Cardiogenic Shock?

Trans-Valvular LV Support: a Glimpse Into the Future

Intra-Aortic Balloon Counterpulsation: "I'll Be Back"

Treating the Right Ventricle in Cardiogenic Shock: the Next Frontier in Improving Outcomes

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Biomarkers and Risk Stratification for Cardiogenic Shock

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

LVAD Associated Aortic Regurgitation: Treatment With a Dedicated TAVR System

TCT 640: POST MYOCARDIAL INFARCTION VENTRICULAR SEPTAL RUPTURE WITH HEART FAILURE AND CARDIOGENIC SHOCK : CHALLENGES AND DEVICE CLOSURE

TCT 688: An Unfortuante Trifecta: A case of  acute myocardial infarction with cardiogenic shock, pericardial tamponade, and worsening hypoxia with right to left shunt after percutaneous LVAD placement.

TCT 611: Amniotic Fluid Embolism-Induced Cardiopulmonary Collapse Successfully Treated with Combination VA-ECMO and Impella CP

TCT 774: Transcatheter Edge-to-Edge Repair in Primary Severe Mitral Regurgitation Complicated by Cardiogenic Shock 

TCT 808: Cardiogenic Shock and Severe MR treated with NTW MitraClip: Bridge to stabilization - GDMT

TCT 638: Sequential transcatheter treatment of severe mitral and aortic regurgitation with MitraClip and JenaValve Trilogy in a patient with cardiogenic shock

Cardiogenic Shock Trials: Defining the Clinical Need and Framing the Issues

Is There a Role for MCS in Massive PE and Which Modality?

Assembling the Safest Solution for Hemodynamic Support in Heart Failure (Puzzle Medical)